Department of Medical Oncology, Royal North Shore Hospital, St. Leonards, New South Wales, Australia;
Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, University of Sydney, Sydney, New South Wales, Australia.
J Nucl Med. 2021 Sep 1;62(9):1278-1284. doi: 10.2967/jnumed.120.257659. Epub 2021 Feb 12.
PET scans using F-FDG and somatostatin receptor imaging agents are both used in imaging of neuroendocrine neoplasms (NENs). We have suggested the "NETPET score," using uptake of both PET tracers, as a prognostic biomarker in NENs. The name NETPET score was suggested previously to capture the score's intent to summarize information from dual PET imaging in neuroendocrine tumors. We previously demonstrated the effectiveness of the NETPET score in gastroenteropancreatic NENs (GEPNENs). Its prognostic relevance in bronchial NENs remains undetermined. This is a retrospective multicenter study (2011-2018) assessing patients who had advanced bronchial NEN and who underwent both F-FDG and Ga-DOTATATE PET within 60 d of each other. The NETPET score was assigned by experienced nuclear medicine physicians and compared with other clinical data such as World Health Organization grade. The primary outcome was overall survival; NETPET score and other prognostic variables were analyzed using univariate and multivariate analyses by the Cox proportional-hazards model. Thirty-eight patients were included for review. The NETPET score and histology were significantly correlated with overall survival in univariate analyses ( = 0.003, = 0.01). On multivariate analysis, only the NETPET score remained significant ( = 0.03). The NETPET score was significantly associated with histologic grade ( = 0.006, χ test). The NETPET score is a prognostic biomarker in bronchial NENs as well as GEPNENs. Although it needs to be validated in prospective studies, it holds significant promise as a biomarker for a wide range of NENs.
正电子发射断层扫描（PET）使用 F-FDG 和生长抑素受体显像剂均可用于神经内分泌肿瘤（NENs）的影像学检查。我们提出了“NETPET 评分”，使用两种 PET 示踪剂的摄取作为 NENs 的预后生物标志物。NETPET 评分的名称先前是为了概括双重 PET 成像在神经内分泌肿瘤中的信息而提出的。我们之前已经证明了 NETPET 评分在胃肠胰神经内分泌肿瘤（GEPNENs）中的有效性。其在支气管神经内分泌肿瘤中的预后相关性尚不确定。这是一项回顾性多中心研究（2011-2018 年），评估了患有晚期支气管神经内分泌肿瘤且在 60 天内接受 F-FDG 和 Ga-DOTATATE PET 的患者。NETPET 评分由经验丰富的核医学医师分配，并与其他临床数据（如世界卫生组织分级）进行比较。主要结局是总生存；通过 Cox 比例风险模型的单变量和多变量分析，对 NETPET 评分和其他预后变量进行分析。共纳入 38 例患者进行回顾性分析。NETPET 评分和组织学在单变量分析中与总生存显著相关（=0.003，=0.01）。在多变量分析中，只有 NETPET 评分仍然显著（=0.03）。NETPET 评分与组织学分级显著相关（=0.006，卡方检验）。NETPET 评分是支气管神经内分泌肿瘤和胃肠胰神经内分泌肿瘤的预后生物标志物。虽然它需要在前瞻性研究中得到验证，但它作为一种广泛的神经内分泌肿瘤的生物标志物具有重要的应用前景。
